BUT makes sure you morons can't & if they lose these cases GAME OVER for the rest of you recently reprieved donut delivererers (sp) & baby sitters of the deliverererers (sp)
Novartis Sues Dr. Reddy's Over ANDA For Cancer Drug
By Cara Salvatore 0 Comments
Law360, New York (February 06, 2014, 2:45 PM ET) -- Novartis AG sued Dr. Reddy's Laboratories Ltd. on Wednesday, saying the generics maker's plan to market and sell its own version of blockbuster cancer drug Gleevec would infringe a Novartis patent.
Novartis said in a Delaware federal court complaint that Dr. Reddy's abbreviated new drug application would violate the patent for Gleevec, U.S. Patent Number 6,894,051, issued in 2005.
Novartis Sues Noven Over Generic Dementia Patch
By Kira Lerner 0 Comments
Law360, New York (January 31, 2014, 3:27 PM ET) -- Novartis AG hit Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a suit in Delaware federal court Thursday, claiming Noven’s proposed generic version of the Exelon patch, used to treat dementia, infringes patents covering the drug.
According to the Swiss pharmaceutical giant, Japan-based Hisamitsu and two Noven units’ planned 13.3 milligram drug containing the active ingredient rivastigmine and used to treat dementia infringes U.S. Patent Nos. 6,316,023 and 6,335,031, patents jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG.
Novartis Sues Dr. Reddy's Over ANDA For Cancer Drug
By Cara Salvatore 0 Comments
Law360, New York (February 06, 2014, 2:45 PM ET) -- Novartis AG sued Dr. Reddy's Laboratories Ltd. on Wednesday, saying the generics maker's plan to market and sell its own version of blockbuster cancer drug Gleevec would infringe a Novartis patent.
Novartis said in a Delaware federal court complaint that Dr. Reddy's abbreviated new drug application would violate the patent for Gleevec, U.S. Patent Number 6,894,051, issued in 2005.
Novartis Sues Noven Over Generic Dementia Patch
By Kira Lerner 0 Comments
Law360, New York (January 31, 2014, 3:27 PM ET) -- Novartis AG hit Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a suit in Delaware federal court Thursday, claiming Noven’s proposed generic version of the Exelon patch, used to treat dementia, infringes patents covering the drug.
According to the Swiss pharmaceutical giant, Japan-based Hisamitsu and two Noven units’ planned 13.3 milligram drug containing the active ingredient rivastigmine and used to treat dementia infringes U.S. Patent Nos. 6,316,023 and 6,335,031, patents jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG.